27 References

References

1. Aranami T, Yamamura T. “Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS).” Allergology International. 2008;57(2):115-120. doi:10.2332/allergolint.r-07-159
2. Arndt, Andreas, et al. “Conventional Housing Conditions Attenuate the Development of Experimental Autoimmune Encephalomyelitis.” PLoS ONE, edited by Christoph Kleinschnitz, vol. 9, no. 6, June 2014, p. e99794. Crossref, doi:10.1371/journal.pone.0099794.
3. Berer, Kerstin, et al. “Gut Microbiota from Multiple Sclerosis Patients Enables Spontaneous Autoimmune Encephalomyelitis in Mice.” Proceedings of the National Academy of Sciences, vol. 114, no. 40, Oct. 2017, pp. 10719–24. www.pnas.org, doi:10.1073/pnas.1711233114.
4. Chu, Fengna, et al. “Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives.” Mediators of Inflammation, 2018, doi:10.1155/2018/8168717.
5. Çinar BP, Yorgun YG. “What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale.” Noro Psikiyatr Ars. 2018;55(Suppl 1):S69–S75. doi:10.29399/npa.23343
6. Constantinescu, CrisS, and Bruno Gran. “The Essential Role of t Cells in Multiple Sclerosis: A Reappraisal.” Biomedical Journal, vol. 37, no. 2, 2014, p. 34. Crossref, doi:10.4103/2319-4170.128746.
7. DiSano, Krista D., et al. “Differential Neuro-Immune Patterns in Two Clinically Relevant Murine Models of Multiple Sclerosis.” Journal of Neuroinflammation, vol. 16, no. 1, May 2019, p. 109. Springer Link, doi:10.1186/s12974-019-1501-9.
8. Chen et al. “Gut Microbiota Interventions With Clostridium Butyricum and Norfloxacin Modulate Immune Response in Experimental Autoimmune Encephalomyelitis Mice“. Frontiers in Immunology vol.10, no.1, June 2019, p.1662
9. Khailaie, Sahamoddin, et al. “A Mathematical Model of Immune Activation with a Unified Self-Nonself Concept.” Frontiers in Immunology, vol. 4, 2013. Frontiers, doi:10.3389/fimmu.2013.00474.
10. Kordasti, S. Y., Afzali, B. , Lim, Z. , Ingram, W. , Hayden, J. , Barber, L. , Matthews, K. , Chelliah, R. , Guinn, B. , Lombardi, G. , Farzaneh, F. and Mufti, G. J. (2009), IL‐17‐producing CD4⁺ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. British Journal of Haematology, 145: 64-72. doi:10.1111/j.1365-2141.2009.07593.x)
11. Minter, Myles R., et al. “Antibiotic-Induced Perturbations in Gut Microbial Diversity Influences Neuro-Inflammation and Amyloidosis in a Murine Model of Alzheimer’s Disease.” Scientific Reports, vol. 6, July 2016, p. 30028. www-nature-com.myaccess.library.utoronto.ca, doi:10.1038/srep30028.
12. MS Society of Canada, 2019. What Is MS? — MS Society of Canada. https://mssociety.ca/about-ms/what-is-ms. Accessed 7 Nov. 2019.
13. Sampson, Timothy R., et al. “Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease.” Cell, vol. 167, no. 6, Dec. 2016, pp. 1469-1480.e12. PubMed Central, doi:10.1016/j.cell.2016.11.018.
14. Saresella, Marina, et al. “Immunological and Clinical Effect of Diet Modulation of the Gut Microbiome in Multiple Sclerosis Patients: A Pilot Study.” Frontiers in Immunology, vol. 8, Oct. 2017. PubMed Central, doi:10.3389/fimmu.2017.01391.
15. Singh A., Khare M., Gade W., and Zamboni P. “Theranostic Implications of Nanotechnology in Multiple Sclerosis: A Future Perspective,” Autoimmune Diseases, vol. 2012, Article ID 160830, 12 pages, 2012. https://doi.org/10.1155/2012/160830.
16. Trabattoni D, Saresella M, Pacei M et al. “Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease.” The Journal of Immunology. 2009;183(8):4984-4993. doi:10.4049/jimmunol.0901038
17. Tremlett H., Fadrosh D., Lynch S., Hart K., Graves J., Lulu S., et al. “Gut microbiome in early pediatric multiple sclerosis: a case-control study.” Eur J Neurol. 2016;23(8): 1308-1321. doi:10.1111/ene.13026